NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$97.10 +0.37 (+0.38 %)
(As of 07/16/2018 06:00 AM ET)
Previous Close$97.10
Today's Range$95.69 - $98.32
52-Week Range$51.05 - $135.59
Volume366,947 shs
Average Volume727,179 shs
Market Capitalization$2.87 billion
P/E Ratio-6.75
Dividend YieldN/A
Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-6.88
Current Ratio4.58
Quick Ratio4.58


Trailing P/E Ratio-6.75
Forward P/E Ratio-8.57
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.96 million
Price / Sales21.93
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book149.38


EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-241.33%
Return on Equity-573.64%
Return on Assets-68.54%


Outstanding Shares29,580,000
Market Cap$2,872.51

The Truth About Cryptocurrencies

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) posted its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($3.22) EPS for the quarter, beating the Zacks' consensus estimate of ($3.41) by $0.19. The biopharmaceutical company earned $35.96 million during the quarter, compared to analysts' expectations of $38.44 million. Intercept Pharmaceuticals had a negative return on equity of 573.64% and a negative net margin of 241.33%. The business's revenue was up 70.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.61) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

22 brokers have issued 12 month price objectives for Intercept Pharmaceuticals' stock. Their predictions range from $50.00 to $253.00. On average, they expect Intercept Pharmaceuticals' share price to reach $124.35 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View Analyst Ratings for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 3 sell ratings, 8 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC in adults. The uptake of the drug was encouraging till October 2017. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. Nevertheless, the updated label should help the stock turn around and boost demand. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC in late-stage studies. The label expansion of the drug will boost the growth prospects. Moreover, the NASH market represents huge potential and a tentative approval will boost Ocaliva’s prospects. Shares have outperformed the industry in the year so far." (7/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "PBC – Despite headwinds associated with labeling harmonization for Ocaliva and widened gross-to-net impact expected for the earlier portion of the year, scripts for the drug have been reported to have stabilized. We believe efforts towards educating and creating confidence for prescribing physicians may have stemmed the tide and signal the return to revenue growth. While our long-term projections remain conservative (20% at peak), continued execution in the remainder of 2018 could build our confidence and expand opportunity for the shares. That said, we remain cautious on NASH." (5/8/2018)
  • 3. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
  • 4. Wells Fargo & Co analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 50)
  • Mr. David Ford, Chief HR Officer (Age 49)
  • Dr. David Shapiro, Chief Medical Officer (Age 64)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News coverage about ICPT stock has trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.51%), Fisher Asset Management LLC (0.15%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which institutional investors are buying Intercept Pharmaceuticals stock?

ICPT stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Fisher Asset Management LLC and Xact Kapitalforvaltning AB. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $97.10.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.87 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  797 (Vote Outperform)
Underperform Votes:  418 (Vote Underperform)
Total Votes:  1,215
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.